Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Xiaofeng Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6790-0669; OpenAlex author ID A5068870075. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. K11- and K29-ubiquitination-mediated nuclear translocation of glycolytic enzyme aldolase A promotes pancreatic cancer progression by NF-κB activation. Last author DOI 10.1038/s41418-025-01592-7↗
  2. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-20-1484↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuhan Zhao · 1 shared paper, 2026 · strength 0.39
  2. Siru Zhou · 1 shared paper, 2026 · strength 0.39
  3. Kathleen M. McAndrews · 1 shared paper, 2022 · strength 0.13
  4. Julienne L. Carstens · 1 shared paper, 2022 · strength 0.13
  5. Yang Chen · 1 shared paper, 2022 · strength 0.13
  6. Sujuan Yang · 1 shared paper, 2022 · strength 0.13
  7. Raghu Kalluri · 1 shared paper, 2022 · strength 0.13
  8. Huamin Wang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.